Skip to main content
Cannara Biotech Inc. logo

Cannara Biotech Inc. — Investor Relations & Filings

Ticker · LOVE LEI · 875500MHKAAYHYVYZ941 TSXV Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2026-02-06 Regulatory Filings
Country CA Canada
Listing TSXV LOVE

About Cannara Biotech Inc.

https://www.cannara.ca/

Cannara Biotech Inc. is a vertically integrated producer specializing in the cultivation and sale of premium-quality cannabis and cannabis-derivative products for the Canadian recreational and medical markets. The company operates state-of-the-art indoor cultivation facilities spanning over 1,650,000 square feet, designed for high efficiency, sustainability, and low-cost production, with an annualized output capacity of up to 100,000 kg. Cannara offers a wide range of products, including dried flowers, pre-rolls, and oils, marketed under brands such as TRIBAL, nugz, and ORCHID CBD. The company leverages advanced cultivation techniques and scale to deliver consistent, high-quality products at competitive value.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 45-106F1 Report of Exempt Distribution', which is a specific regulatory filing used in Canadian jurisdictions to report the distribution of securities without a prospectus. This document type does not fit into the standard financial reporting categories like 10-K or Earnings Release, nor is it a simple announcement. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for specific regulatory disclosures.
2026-02-06 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a 'Form 51-102F3 Material Change Report' filed by Cannara Biotech Inc. It details two primary events: a strategic private placement (financing) and the results of a shareholder meeting (voting results). While it contains elements of both 'CAP' (Capital/Financing) and 'DVA' (Declaration of Voting Results), the document is structured as a formal regulatory filing under Canadian securities law (National Instrument 51-102) to report material changes. Given the document covers multiple material events and is a formal regulatory disclosure, 'RNS' (Regulatory Filings) is the most appropriate classification as it serves as the catch-all for these types of comprehensive regulatory disclosures.
2026-02-05 English
News release - French.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Cannara Biotech Inc. has received conditional approval to migrate its stock listing from the TSX Venture Exchange (TSXV) to the Toronto Stock Exchange (TSX). This is a corporate announcement regarding exchange listing status and does not fit into specific categories like M&A, earnings, or dividends. As it is a general regulatory announcement regarding company status, it falls under the 'Regulatory Filings' (RNS) category.
2026-01-28 French
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing that Cannara Biotech Inc. has received conditional approval to uplist its shares from the TSX Venture Exchange to the Toronto Stock Exchange (TSX). This is a corporate announcement regarding a change in listing status and capital market structure. Since it does not fit into specific categories like 'Delisting' (as it is an uplisting/transition) or 'Share Issue', and it is a general regulatory/corporate announcement, it is best classified as a Regulatory Filing (RNS).
2026-01-28 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is explicitly titled 'Management Discussion & Analysis' (MD&A) for the three-month period ended November 30, 2025. It provides a detailed narrative explanation of financial results, business trends, and operational outlook, which is the standard content for an MD&A report. It is not a standalone financial statement, nor is it a press release or a short announcement, as it contains extensive sections on forward-looking statements, non-GAAP measures, and operational definitions.
2026-01-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Certification of Interim Filings' (Form 52-109FV2). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like interim filings), should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial data. Q1 2026
2026-01-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.